Sign inCreate account

Report workspace tools

NCT04241211UNKNOWNanonymous

Comparative Study for Incidence of Proximal Junctional Kyphosis Between Parathyroid Hormone and Denosumab Following Adult Spinal Deformity Surgery : A Prospective, Randomized Controlled Trial

Sponsor

Source record

Seoul National University Bundang Hospital

Phase

Source record

Phase 4

Modality

AI-normalized

monoclonal antibody

Target

AI-normalized

Proximal Junctional Kyphosis (PJK)

Indication / condition

AI-normalized

Spine Deformity

Intervention

Source record

Forsteo, Denosumab Prefilled Syringe [Prolia]

Source & freshness

Source record

NCT ID

NCT04241211

Original source

ClinicalTrials.gov

Source last updated

Jan 27, 2020

Ingested at

May 23, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT04241211

Title

Comparative Study for Incidence of Proximal Junctional Kyphosis Between Parathyroid Hormone and Denosumab Following Adult Spinal Deformity Surgery : A Prospective, Randomized Controlled Trial

Sponsor

Seoul National University Bundang Hospital

Status

UNKNOWN

Phase

Phase 4

Condition raw

Spine Deformity

Condition normalized

Spine Deformity

Modality raw

Spine Deformity

Modality normalized

monoclonal antibody

Target raw

Proximal Junctional Kyphosis (PJK)

Target normalized

Proximal Junctional Kyphosis (PJK)

Interventions

Forsteo, Denosumab Prefilled Syringe [Prolia]

Public preview

Source record

This clinical trial investigates the efficacy of Teriparatide (Forsteo) compared to Denosumab (Prolia) in reducing the incidence of Proximal Junctional Kyphosis (PJK) following Adult Spinal Deformity (ASD) surgery. The study is being conducted at Seoul National University Bundang Hospital and aims to provide insights into effective medical therapies for PJK prevention.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Comparative Study for Incidence of Proximal Junctional Kyphosis Between Parathyroid Hormone and Denosumab Following Adult Spinal Deformity Surgery : A Prospective, Randomized Controlled Trial

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT04241211

Status

UNKNOWN

Phase

Phase 4

Sponsor

Seoul National University Bundang Hospital

Executive brief

Investment-Ready Snapshot

This clinical trial investigates the efficacy of Teriparatide (Forsteo) compared to Denosumab (Prolia) in reducing the incidence of Proximal Junctional Kyphosis (PJK) following Adult Spinal Deformity (ASD) surgery. The study is being conducted at Seoul National University Bundang Hospital and aims to provide insights into effective medical therapies for PJK prevention.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedJan 27, 2020
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT04241211

Indication

Spine Deformity

Modality

monoclonal antibody

Target

Proximal Junctional Kyphosis (PJK)

Intervention

Forsteo, Denosumab Prefilled Syringe [Prolia]

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.